Epigenetic Silencing of DAPK1and p16 Genes by CpG Island Hypermethylation in Epithelial Ovarian Cancer Patients. 2021

Mariyam Zuberi, and Sagar Dholariya, and Imran Khan, and Rashid Mir, and Sameer Guru, and Musadiq Bhat, and Mamta Sumi, and Alpana Saxena
Department of Biochemistry, Maulana Azad Medical College, New Delhi, 110002 India.

Transcriptional silencing induced by hypermethylation of CpG islands in the promoter regions of genes is believed to be an important mechanism of carcinogenesis in human cancers including epithelial ovarian cancer (EOC). Previously published data on gene methylation of EOC focused mainly on single gene or on cancer tissues. Objectives of the study were to estimate the promoter hypermethylation status of DAPK1 and p16 genes in circulating blood of EOC patients and to determine their association with clinicopathological features of EOC. This case-control study included 50 EOC patients and 20 apparently healthy and age matched female controls. Isolation of genomic DNA was carried out from peripheral venous blood. Methylation in promoter region of DAPK1 and p16 genes was determined by methylation-specific PCR. Methylation of DAPK1 was occurred in 42 out of 50 cases (84.0%) and methylation of p16 gene was occurred in 34 out of 50 cases (68.0%). Methylation of both genes was occurred in 25 cases (50.0%). Occurrence of methylation in DAPK1 and p16 genes was statistically significant (p < 0.0001) in cases compared to controls. Methylation of both genes was not statistically associated with age at diagnosis, menopausal status, histopathological types and FIGO staging of EOC. Identification of the peculiar promoter hypermethylation of DAPK1 and p16 genes might be a successful approach for ancillary diagnosis of EOC at early stage in blood sample.

UI MeSH Term Description Entries

Related Publications

Mariyam Zuberi, and Sagar Dholariya, and Imran Khan, and Rashid Mir, and Sameer Guru, and Musadiq Bhat, and Mamta Sumi, and Alpana Saxena
November 2006, Cancer biology & therapy,
Mariyam Zuberi, and Sagar Dholariya, and Imran Khan, and Rashid Mir, and Sameer Guru, and Musadiq Bhat, and Mamta Sumi, and Alpana Saxena
June 2018, Oncotarget,
Mariyam Zuberi, and Sagar Dholariya, and Imran Khan, and Rashid Mir, and Sameer Guru, and Musadiq Bhat, and Mamta Sumi, and Alpana Saxena
May 2013, Cancer cell international,
Mariyam Zuberi, and Sagar Dholariya, and Imran Khan, and Rashid Mir, and Sameer Guru, and Musadiq Bhat, and Mamta Sumi, and Alpana Saxena
May 2008, World journal of gastroenterology,
Mariyam Zuberi, and Sagar Dholariya, and Imran Khan, and Rashid Mir, and Sameer Guru, and Musadiq Bhat, and Mamta Sumi, and Alpana Saxena
June 2012, RNA biology,
Mariyam Zuberi, and Sagar Dholariya, and Imran Khan, and Rashid Mir, and Sameer Guru, and Musadiq Bhat, and Mamta Sumi, and Alpana Saxena
December 2004, International journal of cancer,
Mariyam Zuberi, and Sagar Dholariya, and Imran Khan, and Rashid Mir, and Sameer Guru, and Musadiq Bhat, and Mamta Sumi, and Alpana Saxena
December 2014, International journal of oncology,
Mariyam Zuberi, and Sagar Dholariya, and Imran Khan, and Rashid Mir, and Sameer Guru, and Musadiq Bhat, and Mamta Sumi, and Alpana Saxena
October 2015, Toxicology and industrial health,
Mariyam Zuberi, and Sagar Dholariya, and Imran Khan, and Rashid Mir, and Sameer Guru, and Musadiq Bhat, and Mamta Sumi, and Alpana Saxena
March 2006, Oncology reports,
Mariyam Zuberi, and Sagar Dholariya, and Imran Khan, and Rashid Mir, and Sameer Guru, and Musadiq Bhat, and Mamta Sumi, and Alpana Saxena
May 2010, Acta obstetricia et gynecologica Scandinavica,
Copied contents to your clipboard!